The long view
A treatment finally emerges for long COVID fatigue
Long COVID fatigue has been one of medicine's most disabling and least understood complaints, with no proven treatment despite sidelining millions of people from work and family life. A randomized trial testing existing, inexpensive drugs against placebo has begun to identify what actually helps and by how much.
Latest · Jul 19, 2026 In a placebo-controlled trial of 399 adults in Brazil who had unrelenting post-COVID fatigue for at least 90 days, researchers led by Edward Mills of McMaster University found fluvoxamine, a cheap antidepressant on the market since the 1990s, had a 99 percent probability of beating placebo on fatigue, while metformin was also tested in the same trial.
What’s next: Whether the fatigue benefit holds past the 60-day trial window, and why an antidepressant helps a symptom that is not itself depression.
Follow this storyline → Don't miss a week.
We send the good news every morning, and it adds up to this. One short, warm letter a day, free forever.
Free forever, no spam. One click to unsubscribe, and we never sell your email.